galectin-slider-v1-670x220

News

Galectin Therapeutics to Present at the Singular Research Summer Conference

July 7, 2017 | Press Release

Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics

June 21, 2017 | Press Release

Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial

June 13, 2017 | Press Release

Videos

Why did you choose to become the CEO of Galectin Therapeutics?

Are you conducting clinical trials with GR-MD-02? What results have you seen so far?

Can you give me a quick overview of Galectin Therapeutics and the opportunity it sees for GR-MD-02?

Why are the results of the GR-MD-02 psoriasis study so promising?

Why is the NASH-CX trial so important?

Galectin Therapeutics, Inc.

NASDAQ: GALT

Financial Tear Sheet
Filings & Reports

Stock price updates every 30 minutes.

Corporate Snapshot

Subscribe